Following our prior study [8], we compared three key clinical outcomes (i.e., pain intensity, physical function, and depression) and four ORAE outcomes (i.e., opioid-related hospitalizations and ED visits, opioid use disorder [OUD], and opioid overdose [OD]) among patients with CYP2D6-inhibiting versus CYP2D6-neutral antidepressants, concomitantly used with newly-prescribed CYP2D6-metabolized opioids. The gene discussed is CYP2D6; the disease is depressive symptom measurement.